68 88

Cited 29 times in

Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.

Authors
 Ho-Young Yhim  ;  Jin Seok Kim  ;  Yeung-Chul Mun  ;  Joon Ho Moon  ;  Yee Soo Chae  ;  Yong Park  ;  Jae-Cheol Jo  ;  Seok Jin Kim  ;  Dok Hyun Yoon  ;  June-Won Cheong  ;  Jae-Yong Kwak  ;  Je-Jung Lee  ;  Won Seog Kim  ;  Cheolwon Suh  ;  Deok-Hwan Yang 
Citation
 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, Vol.21(9) : 1597-1604, 2015 
Journal Title
 BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION 
ISSN
 1083-8791 
Issue Date
2015
MeSH
Adolescent ; Adult ; Autografts ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Lymphoma, Extranodal NK-T-Cell/mortality* ; Lymphoma, Extranodal NK-T-Cell/pathology* ; Lymphoma, Extranodal NK-T-Cell/therapy* ; Male ; Middle Aged ; Neoplasm Staging ; Remission Induction ; Stem Cell Transplantation* ; Survival Rate
Keywords
Ann Arbor stage ; Autologous ; Extranodal natural killer/T cell lymphoma ; Prognosis ; Stem cell transplantation
Abstract
Limited data exist on up-front autologous stem cell transplantation (ASCT) in extranodal natural killer/T cell lymphoma (ENKTL). Sixty-two patients (43 men and 19 women) with newly diagnosed ENKTL who underwent up-front ASCT after primary therapy were identified. Poor-risk characteristics included advanced stage (50%), high-intermediate to high-risk International Prognostic Index (25.8%), and group 3 to 4 of NK/T Cell Lymphoma Prognostic Index (NKPI, 67.7%). Pretransplant responses included complete remission in 61.3% and partial remission in 38.7% of patients, and final post-transplantation response included complete remission in 78.3%. Early progression occurred in 12.9%. At a median follow-up of 43.3 months (range, 3.7 to 114.6), 3-year progression-free survival (PFS) was 52.4% and 3-year overall survival (OS) was 60.0%. Patients with limited disease had significantly better 3-year PFS (64.5% versus 40.1%, P = .017) and OS (67.6% versus 52.3%, P = .048) than those with advanced disease. Multivariate analysis showed NKPI and pretransplant response were independent prognostic factors influencing survival, particularly NKPI in limited disease and pretransplant response in advanced disease. Radiotherapy was an independent factor for reduced progression and survival in patients with limited disease, but anthracycline-based chemotherapy was a poor prognostic factor for progression in patients with advanced disease. Up-front ASCT is an active treatment in ENKTL patients responding to primary therapy.
Files in This Item:
T999901266.pdf Download
DOI
10.1016/j.bbmt.2015.05.003
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jin Seok(김진석) ORCID logo https://orcid.org/0000-0001-8986-8436
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/165808
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse